Tabrecta
Tabrecta ingredients
| Active ingredient | Strength |
|---|---|
| Capmatinib Hydrochloride | 150 mg/1, 200 mg/1 |
What Tabrecta is used for
The FDA lists the approved uses on the official label (below). In the EU, capmatinib is approved as Tabrecta for:
Tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Tabrecta
- Generic name
- Capmatinib
- Made by
- Novartis Pharmaceuticals Corporation
- Forms
- Tablet, Film Coated
- Given
- Oral
- Drug class
- Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA213591
- On the US market since
- 2020
Official information
- MedlinePlus drug information (search for Capmatinib)
In India
- Capmatinib hydrochloride: 2 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Tabrecta?
Tabrecta (Capmatinib) is a cancer medicine made by Novartis Pharmaceuticals Corporation, approved by the US FDA.
What are the ingredients of Tabrecta?
Tabrecta contains Capmatinib Hydrochloride (150 mg/1, 200 mg/1).
Is Tabrecta approved in Europe?
The same active substance is approved in the EU as Tabrecta.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA